Biologics: how far can they go in Crohn's disease?

Authors:
Dunleavy KA; Pardi DS.

Journal:
Gastroenterol Rep (Oxf)

Publication Year: 2022

DOI:
10.1093/gastro/goac049

PMCID:
PMC9522383

PMID:
36196255

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Gastroenterol Rep (Oxf)

Abbreviation: Gastroenterol Rep (Oxf)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A novel location classification system for Crohn's disease based on small bowel involvement: a bett…
Guo H; Tang J; Qin X and 6 more (2024) - Transparency Score: 3/6
An unusual interventional approach to treat Type 2 Abernethy malformation in children: two case rep…
Yan J; Yin J; Zhang D and 3 more (2024) - Transparency Score: 3/6
Esophageal mucosa exfoliation: a rare case during endoscopic submucosal dissection.
Tang L; Luo R; Wu Z and 2 more (2024) - Transparency Score: 3/6
Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South o…
Pinazo-Bandera JM; Aranda J; García-García AM and 18 more (2024) - Transparency Score: 3/6
Heterogeneity of immune infiltration and immunotherapy in colorectal cancer.
Li Y; Hu J; Zhi M. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest K.A.D. has no conflicts of interest. D.S.P. has research grants from Seres Therapeutics, Vedanta, Finch, Takeda, and Applied Molecular Transport, and consults for Seres Therapeutics, Vedanta, Immunic Therapeutics, Abbvie, Otsuka, Ferring, Rise Therapeutics, Boehringer Ingelheim, and Summit."

Evidence found in paper:

"Funding None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025